Bristol-Myers Squibb (BMY) said late Thursday that the US Food and Drug Administration has updated prescribing information for the company's cardiac myosin inhibitor Camzyos to reduce echocardiography monitoring requirements and contraindications.
The regulator streamlined treatment for patients and physicians by lowering the required echo monitoring for eligible participants in the maintenance phase to every six months from once every 12 weeks, and expanding patient eligibility by reducing contraindications, the company added.
The FDA's decision was based on clinical and real-world data, including results from the Camzyos risk evaluation and mitigation strategy program, Bristol-Myers said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.